KBC Group
IMVT icon

KBC Group’s Immunovant IMVT Stock Holding History

KBC Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$83K Sell
2,459
-1,031
-30% -$40.6K ﹤0.01% 1500
2026
Q2 		$134K Hold
3,490
– – ﹤0.01% 1237
2026
Q1 		$87K Hold
3,490
– – ﹤0.01% 1408
2025
Q4 		$89K Hold
3,490
– – ﹤0.01% 1362
2025
Q3 		$56K Buy
3,490
+1,683
+93% +$27.2K ﹤0.01% 1607
2025
Q2 		$29K Sell
1,807
-1,735
-49% -$26.2K ﹤0.01% 1702
2025
Q1 		$61K Buy
3,542
+443
+14% +$9.27K ﹤0.01% 1728
2024
Q4 		$77K Buy
3,099
+1,163
+60% +$33K ﹤0.01% 1693
2024
Q3 		$55K Buy
1,936
+612
+46% +$18K ﹤0.01% 1664
2024
Q2 		$35K Hold
1,324
– – ﹤0.01% 1779
2024
Q1 		$43K Hold
1,324
– – ﹤0.01% 1632
2023
Q4 		$56K Buy
1,324
+406
+44% +$14.9K ﹤0.01% 1443
2023
Q3 		$35K Buy
+918
New +$20.8K ﹤0.01% 1706

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

KBC Group's IMVT Position: Q3 2026 in Review

KBC Group reduced its Immunovant (IMVT) stake by 30% in Q3 2026, selling an estimated $40.6K and leaving 2,459 shares worth $83K. The position accounts for ﹤0.01% of the portfolio, ranked #1500.

KBC Group first reported a position in IMVT in Q3 2023 and has held it in 13 quarters since. The position peaked at $134K in Q2 2026. 160 funds tracked by Wall St. Rank hold IMVT as of Q3 2026.

  • KBC Group held 2,459 shares of Immunovant worth $83K as of Q3 2026.
  • KBC Group sold 1,031 Immunovant shares in Q3 2026, an estimated $40.6K.
  • Immunovant made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1500 holding.
  • KBC Group first reported a position in Immunovant in Q3 2023 and has held it in 13 quarters since.
  • KBC Group's Immunovant position peaked at $134K in Q2 2026.
  • 160 funds tracked by Wall St. Rank held Immunovant as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.